The Power of Patient-Reported Outcomes Measures in Value-Based Care
By João L. Carapinha
November 3, 2023
Patient-Reported Outcomes Measures (PROMs) have emerged as a pivotal tool in healthcare. Healthcare settings have applied PROMs in numerous instances since the advent of Value-Based Care (VBC), gaining valuable insights into patients’ perceptions of their health and treatment outcomes.
PROMs in VBC
According to the FDA, PROMs are “reports coming directly from patients about how they feel or function in relation to a health condition and its therapy, without interpretation by healthcare professionals or anyone else.” Essentially, the definition emphasizes patient-centred care, where patients’ experiences and outcomes are central to healthcare delivery. However, this begs the question: Are the current methods of capturing PROMs sufficient, or can we leverage today’s advanced technologies to optimise this process? The answer lies in the potential of artificial intelligence (AI) and electronic Patient-Reported Outcomes (ePROs).
Enhancing PROMs with AI and ePROs
Integrating PROs can significantly improve the patient journey, from symptom screening to treatment planning. This approach enables continuous feedback, providing real-time evidence of outcomes without the need for numerous follow-ups. The dynamic nature of this process also improves the perceived value of the cost per episode (CPE) for the patient. AI tools can augment this area further by providing tailored support based on the severity of illness, eliminating the inefficiencies and frustrations caused by inappropriate care levels. For instance, an oncology trial in 2016 utilised a web-based symptom reporting system to automatically alert clinicians about reported symptoms. The system, although not AI-based, proved cost-effective, improved patient survival, reduced emergency visits, and enhanced the quality of life (QoL).
The Future of PROMs in Healthcare
NICE stated that evaluation of such solutions is necessary in the future. However, one must not lose sight of the patient’s perspective amidst the rush towards a digital space.
Previous articles discussed the risk of these solutions lacking a patient-centred approach and provided other “moonshot” solutions to address this. The lack of patient or person-centred care dehumanises the care continuum which poses a risk to VBC. The potential of a PRO model lies in its dual approach: as an input into an AI model predicting an outcome, and as an output from an AI model predicting changes in symptoms or QoL. This captures the lived experience of the patient. In a pilot study, the system demonstrated its ability to predict the likelihood of patients achieving Minimal Important Clinical Difference (MCID). This was after a Total Knee Arthroplasty (TKA). However, the design’s fragmented nature and lack of representation of the diverse population it serves remain significant challenges. Biases in AI and validated system training limitations can skew the model. This could perpetuate many of the inherent issues. To mitigate these challenges, it’s recommended that PROs become standard practice, prioritised, and incorporate the patient experience as a key metric. Careful consideration must be given to PROMs integration. The focus must be user-centred to ensure ease of use and optimised workflows. International guidelines such as The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) highlight elements of good design. The inclusion of these systems has the potential to improve health and QoL by supporting better and faster patient-centred care. To ensure clinician utilization and patient integration, we need to take several steps. These steps will help in achieving a high-value outlook. Patient-Reported Outcomes Measures, augmented by these tools, can significantly influence healthcare system navigation, optimising the continuum of care, and improving outcomes.
🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?
Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.
Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.
🌟 How can personalized medicine transform breast cancer treatment in Spain?
The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.
Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.
🌟 Are we on the brink of transforming breast cancer treatment?
NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.
Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.